ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0046

Association of Genetic Variation in XIST and FTX with Susceptibility to Female-Biased Systemic Autoimmune Disease

Thomas Riley1, Dana DiRenzo1, Ellen Romich2, Michael Levin3, Scott Damrauer3, Michael George1, Montserrat Anguera1, Joshua Baker1 and Nikhil Jiwrajka1, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Media, PA, 3University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA

Meeting: ACR Convergence 2025

Keywords: gender, genomics, Sjögren's syndrome, Systemic lupus erythematosus (SLE), Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0019–0048) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The mechanisms underlying female sex bias in autoimmune diseases remain unclear. Recent work has suggested that impaired maintenance of X-chromosome inactivation (XCI) in female murine immune cells can result in systemic lupus erythematosus (SLE)-like phenotypes. XIST (X-linked) encodes a long non-coding (lnc) RNA that helps maintain XCI in XX individuals. The Genome-Tissue Expression (GTEx) study has identified genetic variants that are expression quantitative trait loci (eQTL) for XIST or its X-linked positive regulator lncRNA FTX. This study hypothesized that eQTLs which lead to decreased expression of XIST or FTX in immune tissue would be positively associated with risk of female-biased autoimmunity.

Methods: Participants in this study come from the Penn Medicine Biobank (PMBB), a health system-based biorepository. Participants underwent genotype sequencing using the Illumina Global Sequencing Array v2 by the Regeneron Genetics Center (Tarrytown, NY). Imputation was performed using the TOPMED Imputation Server. eQTLs associated with decreased expression of XIST and FTX in human splenic tissue were identified using the GTEx portal. Cases were identified using ICD-code and medication algorithms for SLE, systemic sclerosis (SSc), dermatomyositis or polymyositis (immune mediated myopathy, IMM), and Sjögren’s Disease (SjoD). RA, a more modestly sex-biased disease not previously associated with X chromosome dosage, was selected as a negative control outcome. Logistic regression was performed to test the association of eQTLs with female-biased autoimmune disease, adjusted for the first 10 principal components of population structure and stratified by female sex. Using the Benjamini-Hochberg false discovery rate, a p-value < 0.0056 was considered significant.

Results: Among 43,590 individuals in PMMB, 21,690 (49.8%) were female (Table 1). By autoimmune condition, 546 (1.3%) had RA, 319 (0.8%) had SjoD, 306 (0.7%) had SLE, 147 (0.4%) had SSc, and 89 (0.2%) had IMM, with a higher prevalence in females compared to males. eQTLs associated with decreased FTX in the spleen were associated with increased risk for SLE in females; the strongest associations were for rs201911656 (T >TA) with OR 1.57, but did not meet experiment-wide significance thresholds (p = 0.009, Fig. 1, Table 2). eQTLs associated with decreased XIST expression were not statistically significant for individual conditions, including RA (Fig. 1). Examining the risk in diseases previously associated with X chromosome dosage (SLE, IMM, SjoD, and SSc), both XIST and FTX eQTLs were associated with higher odds of pooled autoimmune disease amongst females, but this result was not statistically significant (FTX rs11796715 (C >T) OR 1.21, 95% CI 1.02-1.45, p = 0.03).

Conclusion: Genetic variation associated with altered expression of regulators of XCI maintenance in immune cells was associated with increased risk for specific female-biased autoimmune disease, but did not reach experiment wide-significance thresholds. These results further suggest that impaired regulation of X chromosome dosage via decreased XIST expression may contribute to the female bias of SLE and other systemic autoimmune diseases.

Supporting image 1Table 1. Demographic and Disease Statistics within Penn Medicine Biobank

Supporting image 2Figure 1. Heat Map of eQTL and sex-biased autoimmune conditions within the Penn Medicine Biobank. eQTLs for FTX were associated with statistically significantly higher odds of systemic lupus, immune mediated myopathy, and pooled sex-biased autoimmune disease. Analysis was performed using logistic regression, adjusted for the first 10 principal components of population structure and restricted to female sex. *Bold font indicates associations with p < 0.05; no associations met the experiment-wide significance threshold < 0.0056.

Abbreviations: RA – Rheumatoid Arthritis; SLE – Systemic Lupus Erythematosus; SjoD – Sjogren’s Disease: ICD – International Classification of Disease; IMM – Immune Mediated Myopathy; SSc – Systemic Sclerosis; ACR – American College of Rheumatology.

Supporting image 3Figure 2. Association with autoimmune disease and FTX eQTL rs201911656. Logistic regression was performed to test the association of eQTL in an additive model with the female-biased autoimmune disease, adjusted for the first 10 principal components of population structure and restricted to female sex.

Abbreviations: RA – Rheumatoid Arthritis; SLE – Systemic Lupus Erythematosus; SjoD – Sjogren’s Disease: ICD – International Classification of Disease; IMM – Immune Mediated Myopathy; SSc – Systemic Sclerosis; ACR – American College of Rheumatology.


Disclosures: T. Riley: None; D. DiRenzo: Amgen, 2, Novartis, 2, Sjogren's Foundation, 5; E. Romich: Lungpacer Medical, Inc., 11, Teva Pharmaceuticals, 12, Spouse employment; M. Levin: None; S. Damrauer: Amgen, 12, Non-financial research support, Novo Nordisk, 12, Non-financial research support, US Department of Veterans Affairs, 10; M. George: Boehringer-Ingelheim, 2, GlaxoSmithKlein(GSK), 5, Janssen, 5, Pfizer, 2, 5; M. Anguera: None; J. Baker: Amgen, 5; N. Jiwrajka: None.

To cite this abstract in AMA style:

Riley T, DiRenzo D, Romich E, Levin M, Damrauer S, George M, Anguera M, Baker J, Jiwrajka N. Association of Genetic Variation in XIST and FTX with Susceptibility to Female-Biased Systemic Autoimmune Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/association-of-genetic-variation-in-xist-and-ftx-with-susceptibility-to-female-biased-systemic-autoimmune-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-genetic-variation-in-xist-and-ftx-with-susceptibility-to-female-biased-systemic-autoimmune-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology